CVKD Insider Trading

Insider Ownership Percentage: 48.62%
Insider Buying (Last 12 Months): $75,831.70
Insider Selling (Last 12 Months): $0.00

Cadrenal Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cadrenal Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cadrenal Therapeutics Share Price & Price History

Current Price: $0.45
Price Change: Price Decrease of -0.0051 (-1.12%)
As of 07/25/2024 02:48 PM ET

This chart shows the closing price history over time for CVKD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Cadrenal Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2023John Raymond MurphyDirectorBuy17,331$0.70$12,131.70612,123View SEC Filing Icon  
9/1/2023Quang X PhamCEOBuy70,000$0.91$63,700.003,370,000View SEC Filing Icon  
3/21/2023John Raymond MurphyDirectorBuy10,000$1.39$13,900.00594,792View SEC Filing Icon  
3/16/2023John Raymond MurphyDirectorBuy20,000$1.67$33,400.00574,792View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cadrenal Therapeutics (NASDAQ:CVKD)

7.92% of Cadrenal Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cadrenal Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC414,285$0.31M0.0%-57.8%3.182%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC982,285$0.67M0.0%N/A7.544%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cadrenal Therapeutics logo
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Read More on Cadrenal Therapeutics

Today's Range

Now: $0.45
Low: $0.44
High: $0.46

50 Day Range

MA: $0.45
Low: $0.40
High: $0.51

52 Week Range

Now: $0.45
Low: $0.36
High: $2.17

Volume

27,811 shs

Average Volume

259,762 shs

Market Capitalization

$7.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Who are the company insiders with the largest holdings of Cadrenal Therapeutics?

Cadrenal Therapeutics' top insider investors include:
  1. Quang X Pham (CEO)
  2. John Raymond Murphy (Director)
Learn More about top insider investors at Cadrenal Therapeutics.